Changes in Escherichia coli resistance patterns during and after antibiotic therapy: a longitudinal study among outpatients in Germany E. Raum, S. Lietzau, H. von Baum, R. Marre, H. Brenner Clinical Microbiology and Infection Volume 14, Issue 1, Pages 41-48 (January 2008) DOI: 10.1111/j.1469-0691.2007.01841.x Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions
Fig. 1 Prevalence of resistance among Escherichia coli isolates on the day of practice visit (t0), after a further 7 days (t1), and after 14 days (t2) for patients (a) without antibiotic therapy, (b) receiving β-lactam antibiotics, (c) receiving doxycycline, (d) receiving co-trimoxazole, and (e) receiving a fluoroquinolone. AMP, ampicillin; AMC, co-amoxyclav; TZP, piperacillin–tazobactam; CPD, cefpodoxime; CXM, cefuroxime; DOX, doxycycline; GEN, gentamicin; SXT, co-trimoxazole; NAL, nalidixic acid, LVX, levofloxacin. Clinical Microbiology and Infection 2008 14, 41-48DOI: (10.1111/j.1469-0691.2007.01841.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions